Genmab A/S
27.04.2011 13:28
Dissemination of a Adhoc News, transmitted by DGAP - a company of
EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
? Worldwide net sales of Arzerra in Q1 2011 totaled GBP 9.4 million (DKK
82.1 million)
? Genmab expects royalty payment of DKK 16.4 million
Copenhagen, Denmark; April 27, 2011 - Genmab A/S (OMX: GEN) announced today
that the net sales for Arzerra(r) (ofatumumab) during the first quarter of 2011
were GBP 9.4 million (approximately DKK 82.1 million). Arzerra first quarter
net sales in the U.S. and the rest of the world were GBP 6.7 million
(approximately DKK 58.5 million) and GBP 2.7 million (approximately DKK 23.6
million) respectively. Under the terms of the collaboration with
GlaxoSmithKline (GSK), Genmab expects to receive a royalty payment of
approximately DKK 16.4 million.
The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the first quarter of 2011 of GBP 1.00 = DKK 8.7330.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for the potential treatment of cancer.
Genmab's world class discovery and development teams are using cutting-edge
technology to create and develop products to address unmet medical needs. Our
primary goal is to improve the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
Contact:
Helle Husted, Vice President, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: h.husted@genmab.com
This Stock Exchange Release contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
product discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of our
products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
section 'Risk Management' in Genmab's Annual Report, which is available on
www.genmab.com. Genmab does not undertake any obligation to update or revise
forward looking statements in this Stock Exchange Release nor to confirm such
statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax-EGFr?;
HuMax-IL8?; HuMax-TAC?; HuMax-CD38?; HuMax-TF?; HuMax-Her2?; HuMax-cMet?;
HuMax-CD74?; DuoBody? and UniBody(r) are all trademarks of Genmab A/S.
Arzerra(r)
is a trademark of GlaxoSmithKline.
Genmab A/S
Bredgade 34
1260 Copenhagen K, Denmark
Tel: +45 7020 2728
Fax: +45 7020 2729
www.genmab.com
Stock Exchange Release no. 17
Page 1/1
CVR no. 2102 3884
News Source: NASDAQ OMX
27.04.2011 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-Adhoc: Arzerra first quarter 2011 net sales figures
| Source: EQS Group AG